San Diego, CA, September 24, 2017 --(PR.com
)-- The 4th Annual World ADC Awards Ceremony took place the evening of September 21 at the Sheraton San Diego Marina at 7:15pm.
The Awards are sponsored by Abbvie (Headline Sponsor), Immunogen (Long Standing Contribution to the Field), Ambrx (Best ADC Platform Technology) and Medimmune (Best Publication 2016).
The Awardees were shortlisted from over 1600 votes cast and scientific proposals from each submission were evaluated by our Judging panel.
Fiona Mistri, Program Director, World ADC San Diego stated, “Every year the judges are impressed with the level of innovation and scientific breakthroughs that these companies are driving. This year is no exception and we are delighted to see the calibre and quantity of entries – showing the growing momentum and advances being made within the industry.”
Jagath Reddy Junutula, Cellerent Therapeutics and judge of the Awards said, "The World ADC Awards showcase excellence within the antibody-drug conjugate (ADC) field. This year's winners represent once again the dedication, leadership and innovation that exists in this crucial area of oncology therapeutics. These Awards shine a spotlight on these companies leading the field and as a judge once again I was delighted to see the growing momentum and progress within the field.”
The 2017 winners are:
Best Platform Technology (sponsored by Ambrx)
Winner: Bicycle Therapeutics
Runner Up: Synaffix
Most Promising Clinical Candidate
Winner: ImmunoGen (Mirvetuximab soravtansine)
Runner Up: Stemcentrx (Rova-T)
Best CMO Provider
Runner Up: BSP Pharmaceuticals
Best New Drug Developer:
Runner Up: Heidelberg Pharma
Best CRO Provider
Runner Up: Syngene International Ltd.
Best Publication 2016 (sponsored by Medimmune)
Winner: A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.
Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR.
Cancer Cell. 2016 Jan 11;29(1):117-29. doi: 10.1016/j.ccell.2015.12.008.
Runner Up: Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.
Staben LR1, Koenig SG1, Lehar SM1, Vandlen R1, Zhang D1, Chuh J1, Yu SF1, Ng C1, Guo J1, Liu Y1, Fourie-O'Donohue A1, Go M1, Linghu X1, Segraves NL1, Wang T2, Chen J2, Wei B1, Phillips GD1, Xu K1, Kozak KR1, Mariathasan S1, Flygare JA1, Pillow TH1.
Nat Chem. 2016 Dec;8(12):1112-1119. doi: 10.1038/nchem.2635.
Individual Input to the Field 2016
Long Standing Contribution
Jagath Reddy Junutula
For more information about the World ADC Awards visit http://worldadc-awards.com/
About World ADC San Diego
Focused on ADCs and crafted with the field’s thought-leaders, World ADC is the industry’s definitive forum for learning and networking.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company’s lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen’s ADC technology to develop anticancer therapies; it is used in Roche’s marketed product, Kadcyla.
Ambrx®, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties. We call this process Protein Medicinal Chemistry™. Protein Medicinal Chemistry™ can optimize any protein or antibody to create potentially best-in-class therapeutics such as long-acting proteins, bi-specifics and antibody drug conjugates. This allows us to safely and effectively target cytotoxic agents or recruit effector function to tumor cells (oncology) or modulate biological pathways implicated in disease areas such as autoimmune, metabolic and cardiovascular. At Ambrx, we are dedicated to assembling and developing an exceptional team and a novel technology to create the next generation of protein-based medicines.
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers, with additional sites in Cambridge, UK and Mountain View, CA.